Clinical evaluation.
Thorough psychiatric evaluation in-person or via telehealth. Your provider reviews your treatment history, symptoms, conditions, and medications. If ketamine isn't appropriate, we'll tell you that and discuss alternatives.
Medically supervised ketamine sessions for adults with treatment-resistant depression, PTSD, and severe anxiety. Evaluated and directed start to finish by our board-certified prescriber, with a trained clinical team member monitoring each session at our Wesley Chapel clinic.
We will match you with the right provider and get you on the calendar - usually within one business day.
A care coordinator will reach out within one business day. If you would rather not wait, call (813) 670-3005.
For when standard care hasn't worked.
You've probably already done the research. You've read about response rates, looked up clinics, and weighed whether the cost is worth it. If you've tried two or more antidepressants without adequate relief and you're still struggling, ketamine therapy is a treatment option worth discussing with a provider who knows the research and will be straight with you about what it can and can't do.
Ketamine is a Schedule III controlled substance and should be administered only under medical supervision. Not FDA-approved for depression, PTSD, anxiety, and pain. Individual responses vary - there is no guarantee of response.
Real treatment room · Wesley Chapel
Ketamine therapy at Ascend begins with a full psychiatric evaluation - no exceptions. Before any treatment is scheduled, your provider reviews your diagnostic history, prior medication trials, and clinical trajectory. The evaluation determines whether ketamine is appropriate for you - and if it isn't, you'll hear that clearly, along with alternatives worth exploring.
Because ketamine treatment at Ascend is integrated with our psychiatry practice, your provider can coordinate directly if your broader psychiatric plan needs adjustment - no external referral required.
There is no shortcut. The evidence supports a structured induction series followed by maintenance based on individual response.
Thorough psychiatric evaluation in-person or via telehealth. Your provider reviews your treatment history, symptoms, conditions, and medications. If ketamine isn't appropriate, we'll tell you that and discuss alternatives.
Six sessions over two to three weeks. Each session is approximately two hours total. Clients are required to have a ride home after ketamine therapy.
After induction, your board-certified prescriber will evaluate your response and set a maintenance schedule if needed.
The primary indication. Defined as failure to respond adequately to two or more antidepressant medications at therapeutic doses.
Learn MoreMajor depressive disorder not responsive to standard antidepressants, evaluated case by case as an adjunctive option coordinated with your broader psychiatric plan.
Learn MoreWhen standard treatments - including trauma-focused therapy and first-line medications - have not produced sufficient relief. Ketamine is not FDA-approved for PTSD.
Learn MoreTreatment-resistant anxiety that hasn't responded to standard pharmacological and therapeutic approaches. Evaluated case by case - not all anxiety presentations are appropriate candidates.
Learn MoreOCD that has not responded to first-line therapy and medication trials. Ketamine is not FDA-approved for OCD, and its use is evaluated individually during your psychiatric consultation.
Learn MoreEvaluated in appropriate clinical context. If you are in crisis, call or text 988 for the Suicide and Crisis Lifeline. Ketamine is not an emergency intervention.
Learn MoreConsidered when medication adjustments alone have not produced adequate relief. Evaluated individually - bipolar presentations require careful clinical assessment before ketamine is considered.
Learn MoreAdjunctive use. Conditions such as CRPS and neuropathic pain evaluated individually. Clinical appropriateness is determined during your psychiatric evaluation.
Learn MoreYour board-certified prescriber handles ketamine evaluations, administration, and follow-up personally - start to finish. Meet the team at our Wesley Chapel clinic before you book.
Call us to discuss whether ketamine is appropriate for your situation, and to review pricing and financing options.
Read this before the rest of the page, because it changes how much weight everything else deserves. Ketamine is not FDA-approved to treat depression, PTSD, anxiety, OCD, or chronic pain. The preparation Ascend uses is compounded, which is not FDA-approved for any use, and the FDA has not reviewed it for safety, effectiveness, or manufacturing quality. That is not fine print. It is the first fact you should be weighing.
Compounded means a pharmacy assembles the preparation instead of a manufacturer producing a finished product and submitting it for review. Compounded preparations are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or manufacturing quality. A licensed prescriber may still prescribe one within the standard of care. What you do not get is the regulatory review that sits behind a medication you pick up at a retail counter, and no clinic can hand that back to you by describing the treatment more confidently.
The FDA has publicly warned about ketamine used for psychiatric conditions without proper monitoring, and specifically about compounded ketamine shipped to people to take at home. So the question worth asking any program you are considering, this one included, is where the medication is given and who is watching you while it works. Our answer: we never mail ketamine to a patient and never hand anyone a supply to self-administer. Every dose is prepared for in-clinic use and given at our Wesley Chapel suite as a subcutaneous injection, with a trained team member present from check-in to discharge, and we do not run nasal-spray or at-home ketamine programs. The preparation given there is compounded and is not FDA-approved. Vital signs are checked before, during, and after, and you stay until the medication has worn off.
One more thing worth knowing while you decide. Most published research on ketamine for depression studied other routes of administration. Ascend uses a subcutaneous injection, which has a smaller body of evidence behind it. We would rather say that plainly than let you assume the studies were run on exactly what we give you.
Choosing this is a two-step process, not a purchase. Before any first dose you complete a full psychiatric evaluation with a licensed prescriber and sign an informed consent covering the compounded, non-FDA-approved status of the medication, its risks, and the alternatives. The risks in that consent are specific, and they are easier to think about now than at the front desk: dissociation during the session, expected and temporary, which is why you are monitored continuously and never left alone; short-term rises in blood pressure and heart rate, checked before and during every session; nausea, managed on site; and, because frequent or long-term use carries a risk of bladder and urinary problems, a deliberate cap on how often you dose, reassessed at every follow-up rather than continued indefinitely. Ketamine is a Schedule III controlled substance with a potential for misuse and dependence. You cannot drive yourself home afterward.
FDA status: The racemic ketamine used at Ascend is a compounded preparation that is not FDA-approved. It is not FDA-approved for these uses.
Controlled substance: Ketamine is a Schedule III controlled substance and is administered only under medical supervision at our Wesley Chapel clinic.
Individual responses vary: Clinical studies suggest ketamine may produce improvement in depressive symptoms in some patients. Not all patients respond. There is no guarantee of response.
The population the research supports most directly is adults with treatment-resistant depression, generally meaning two or more antidepressant trials at a therapeutic dose, for a reasonable duration, without adequate relief. Stopping something after a week because of side effects usually does not count as a completed trial. Bring the actual history and let a prescriber make that call, rather than ruling yourself in or out from a website.
Yes, and often it is. The evaluation is a full psychiatric assessment covering treatment history, current symptoms, medical conditions, everything you currently take, substance use history, and anything that would make dosing unsafe. Some people leave with a plan that has nothing to do with ketamine. Because the prescriber evaluating you is part of Ascend's psychiatry team, a no is a redirect inside the same practice rather than the end of the conversation.
No. Ketamine is not FDA-approved to treat depression, and the preparation used at Ascend is compounded, which is not FDA-approved for any use and has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality. A licensed prescriber may still prescribe it within the standard of care. You sign an informed consent covering exactly that before a first dose.
The clearest signal is short-term reduction in depressive symptoms among adults with treatment-resistant depression. For PTSD the picture is mixed: one randomized trial reported benefit, and a larger multi-site trial in veterans and active duty service members did not. Most of that work used a different route of administration than the subcutaneous injection given here. Group averages are not a forecast for one person, and a meaningful share of patients do not respond at all.
Uncontrolled high blood pressure, certain cardiac conditions, active psychosis, and pregnancy are among the reasons a prescriber will decline or defer. An active substance use disorder needs its own plan first, since ketamine is a Schedule III controlled substance with a potential for misuse and dependence. This is also not an emergency intervention. If you are in crisis, call or text 988 for the Suicide and Crisis Lifeline.
Usually one of three things: a closer look at whether the medication trials you have already done were genuinely optimized, a therapy modality you have not tried, or both together. Ascend's psychiatry and therapy teams work from one chart, so the alternative plan gets built by people already looking at the same history instead of starting over behind a referral.
Schedule a consultation with a board-certified provider. We'll review your history, answer your questions, and give you a straight answer about whether ketamine makes sense for your situation.
Ketamine is a Schedule III controlled substance and should be administered only under medical supervision.
Ketamine therapy is delivered in-person at our Wesley Chapel clinic only. The city pages below cover eligibility, what to expect, and the routing path from your area to the Wesley Chapel suite. Telehealth screening is available statewide before in-person sessions begin.